TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00077883
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
TLK286, cisplatin
Sponsor
Telik